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Unité de Prévention et de Lutte Contre les
Infections Nosocomiales, Université
d’Angers, CHU Angers, 49000 Angers,
France
e-mail: jrzahar@gmail.com
B. Misset
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Abstract Emerging resistance to
antibiotics shows no signs of decline.
At the same time, few new antibac-
terials are being discovered. There is
a worldwide recognition regarding
the danger of this situation. The ur-
gency of the situation and the
conviction that practices should
change led the Société de Réanima-
tion de Langue Française (SRLF) and
the Société Française d’Anesthésie et
de Réanimation (SFAR) to set up a
panel of experts from various disci-
plines. These experts met for the first
time at the end of 2012 and have
since met regularly to issue the fol-
lowing 67 recommendations,
according to the rigorous GRADE
methodology. Five fields were ex-
plored: i) the link between the
resistance of bacteria and the use of
antibiotics in intensive care; ii) which
microbiological data and how to use
them to reduce antibiotic consump-
tion; iii) how should antibiotic
therapy be chosen to limit consump-
tion of antibiotics; iv) how can
antibiotic administration be opti-
mized; v) review and duration of
antibiotic treatments. In each institu-
tion, the appropriation of these
recommendations should arouse
multidisciplinary discussions result-
ing in better knowledge of local
epidemiology, rate of antibiotic use,
and finally protocols for improving
the stewardship of antibiotics. These
efforts should contribute to limit the
emergence of resistant bacteria.
Keywords Antimicrobial
stewardship  Epidemiology 
Microbiological diagnostic
techniques  Pharmacokinetics/
pharmacodynamics 
Therapeutic drug monitoring
Introduction
Emerging resistance to antibiotics shows no signs of de-
cline [1]. At the same time, few new antibacterials are
being discovered [2–4]. There is worldwide recognition of
the danger of this situation [5–7].
Hospitalized patients are the first victims of the in-
creasing resistance of bacteria. Those admitted to
intensive care units are particularly affected [8–10], often
by species resistant to virtually all antibiotics [11–14].
The urgency of the situation and the conviction that
practices should change (using new clinical data and
technical advances) led the Société de Réanimation de
Langue Française (SRLF) and the Société Française
d’Anesthésie et de Réanimation (SFAR) to set up a panel
of experts from various fields. This expert panel met for
the first time at the end of 2012 and has since met regularly
to issue the following recommendations, according to the
rigorous methodology described below.
These recommendations are aimed at intensivists
managing adult and paediatric patients. In the case of the
latter, the literature is often poor. The section headings of
the recommendations should therefore be taken as for-
mulated for the care of adults. If they are valid also for
children, this is specified.
Methodology
These recommendations were drawn up by an expert
panel brought together by the SRLF and the SFAR. The
various disciplines involved in the prescription of an-
tibiotics in intensive care units (critical care,
microbiology, infectious diseases, hospital hygiene, pae-
diatrics) were represented.
Selection and organization of the expert panel
The selection of committee members was based on interest
and expertise in specific aspects such as microbiology,
infectious diseases, infection control, epidemiology etc.
Executive committee members (CB, CM, ML and BM)
were first chosen by the SRLF and the SFAR as was the
expert panel coordinator (JPB). Then, the executive
committee with the expert panel coordinator defined the
questions or fields to be covered (Table 1). They desig-
nated the experts in charge of each question. The latter had
to disclose any financial or non-financial/academic com-
peting interest before participating in that group.
Grading of recommendations
The grading of recommendations assessment, develop-
ment and evaluation (GRADE) system was used to
convey the recommendations [15, 16].
A separate literature search was performed for each
field. Experts worked with executive committee members
to identify pertinent search terms that were included. The
authors were asked to search a minimum of one general
database (i.e. MEDLINE, EMBASE) and the Cochrane
library. For each question, available evidence was sum-
marized in the form of evidence tables. During all the
recommendations process, these tables were shared online
on a specific, dedicated server.
The authors were asked to follow the principles of the
GRADE system to guide assessment of quality of evidence
and to determine the strength of recommendations [15].
The GRADE system is based on a sequential assessment of
the quality of evidence, followed by assessment of the
balance between benefits and risks. Burden and cost are
then considered, leading to development and grading of
each recommendation. Keeping the rating of quality of
evidence and strength of recommendation explicitly sepa-
rate constitutes a crucial feature of the GRADE approach.
This system classifies quality of evidence as high (gra-
de A), moderate (grade B), low (grade C) or very low (grade
D). Randomized trials begin as high-quality evidence but
may be downgraded owing to factors such as study limita-
tions, inconsistent results, and indirectness of evidence,
imprecision or possible reporting bias (Table 2). Although
well-done observational studies generally yield low quality of
evidence, three factors may contribute to produce moderate
or even high quality of evidence: large magnitude effect,
plausible confounding, which would reduce a demonstrated
effect, or dose–response gradient effect (Table 2).
The GRADE system classifies recommendations as
strong (grade 1) or weak (grade 2). The factors influ-
encing this determination are presented in Table 2. The
assignment of strong or weak is considered of greater
clinical importance than a difference in letter level of
quality of evidence. The committee assessed whether the
desirable effects of adherence would outweigh the unde-
sirable effects. The strength of a recommendation reflects
the group’s degree of confidence in that assessment.1
Table 1 Five fields explored by the 54 recommendations
1 There is a link between the resistance of bacteria and the use of
antibiotics in intensive care
2 Which microbiological data and how to use them to reduce
antibiotic consumption?
3 How should antibiotic therapy be chosen to limit consumption of
antibiotics?
4 How can antibiotic administration be optimized?
5 Review and duration of antibiotic treatments
1Thus, a strong recommendation in favour of an intervention re-
flects the panel’s opinion that the desirable effects of adherence to a
recommendation (beneficial health outcomes, lesser burden on staff
and patients, and cost savings) will clearly outweigh the undesir-
able effects (harm to health, more burden on staff and patients, and
greater costs). The potential drawbacks of making strong recom-
mendations in the presence of low-quality evidence were taken into
account. A weak recommendation in favour of an intervention
indicates the judgment that the desirable effects of adherence to a
recommendation probably will outweigh the undesirable effects,
but the panel is not confident about these trade-offs either because
some of the evidence is low quality (and thus uncertainty remains
A strong recommendation is worded as ‘we recommend’
or ‘must be done, must not be done’ and a weak recom-
mendation as ‘we suggest’ or ‘should probably be done,
should probably not be done’. Throughout the document are
a number of statements that either follow graded recom-
mendations or are listed as stand-alone numbered statements
followed by ‘ungraded’ in parentheses (UG). For our group,
these recommendations were not conducive for the GRADE
process. Committee members were familiar with the
GRADE system. Rules were discussed concerning assessing
the body of evidence and committee members were available
for advice throughout the process.
Subgroups agreed electronically on draft proposals
that were then discussed with all the experts. The results
of the discussion were incorporated into the next version
of recommendations and again discussed with the whole
group. Draft recommendations were then mailed to the
group for vote.
The aim was not necessarily to reach a single and
convergent opinion for all proposals, but rather to high-
light points of agreement and points of disagreement or
indecision. Each recommendation was then scored by
each expert on a scale ranging from 1 (incomplete
agreement) to 9 (complete agreement). The collective
scoring was established using a methodology derived
from the RAND/UCLA appropriateness method [18]:
after elimination of the extreme values (outliers), the
median and confidence interval of the scores were cal-
culated. The median defined agreement between the
experts when it was between 7 and 9, disagreement be-
tween 1 and 3 and indecision between 4 and 6. The
agreement, disagreement or indecision were ‘strong’ if
the confidence intervals were within one of three ranges,
namely 1–3, 4–6 or 7–9, and ‘weak’ if they were out of
these ranges. In the absence of strong agreement, the
recommendations were reformulated and again scored
with a view to achieving a better consensus.
Two rounds of scoring were therefore performed and
the 67 recommendations presented below.
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Results
The different recommendations are presented below.
For each field, the recommendations are listed with
quality of evidence and strength in a dedicated table.
The rationale is then summarized for each field but
detailed argumentation and/or additional references can
also be found as electronic supplementary material
(ESM).
Q1: There is a link between the resistance of bacteria
and the use of antibiotics in intensive care
Recommendations are presented in Table 3. There was a
strong agreement in the group for the first two statements.
Nevertheless, it was decided that the literature data did
not allow grading of these items, so they appear as ‘un-
graded’ (UG) in the table.
Rationale
Antibiotic selection pressure is an important determinant
of the emergence and spread of resistance to antibiotics.
Footnote 1 continued
regarding the benefits and risks) or the benefits and downsides are
closely balanced. A weak recommendation might also reflect uncer-
tainty about whether the intervention represents a wise use of resources.
Table 2 GRADE system (adapted from [16, 17])
Criteria for assigning grade of evidencea
Type of evidence
Randomised trial = high
Observational study = low
Any other evidence = very low
Decrease grade if
Serious or very serious limitation to study quality
Important inconsistency
Some or major uncertainty about directness
Imprecise or sparse data
High probability of reporting bias
Increase grade if
Strong evidence of association: significant relative risk of[2
(\0.5) based on consistent evidence from C2 observational
studies, with no plausible confounders
Very strong evidence of association: significant relative risk of[5
(\0.2) based on direct evidence with no major threats to validity
Evidence of a dose response gradient
All plausible confounders would have reduced the effect
Factors that affect the strength of a recommendationb
Quality of evidence
Uncertainty about the balance between desirable and undesirable
effects
Uncertainty or variability in values and preferences
Uncertainty about whether the intervention represents a wise use
of resources
a Quality of evidence is classified as high (grade A), moderate
(grade B), low (grade C), very low (grade D) or ungraded (UG)
b Recommendations are classified as strong (grade 1) or weak
(grade 2)
Moreover, it is one of the few factors (with hand hygiene)
that can be influenced or modified through practice. In
intensive care, studies are above all of uncontrolled be-
fore-and-after design, the main focus of which is not
always bacterial resistance [19–21]. A systematic review
by Kaki et al. [22] confirms this trend. The conclusion can
be drawn that bacteriological ecology in intensive care is
(partially) dependent on the antibiotic policy of a given
unit.
It is worth stressing the importance of using local
epidemiological data on antibiotic resistance because
there are major disparities between European countries
and those of other continents, notably North America.
The susceptibility rate for given species has to be
determined locally. But the actual frequency of pa-
tients infected by these given bacteria is almost as
important.
The DDD should be considered separately from indi-
vidual description of treatments. DDDs recommended by
the World Health Organisation (WHO) often differ sub-
stantially from the doses actually used in intensive care,
particularly in the case of b-lactam antibiotics. They ar-
tificially increase the consumption of antibiotics attributed
to intensive care. Like all aggregate data, they have to be
reduced to a common denominator, usually the number of
days of hospitalization, a value easy to record in intensive
care. Despite these imperfections, the DDD is the most
useful parameter because it can be easily and quickly
recorded and because, to some extent, it enables com-
parisons between intensive care units [23].
Q2: Which microbiological data and how to use them
to reduce antibiotic consumption?
Recommendations are presented in Table 4. For this field,
to grade the strength of recommendations, the group has
paid particular attention to the resource use.
Rationale
Sampling for diagnostic purposes must be done early, if
possible before the onset of antibiotics administration.
The quality of microbiological examinations depends on
the information given to the laboratory, the choice and
methods of sampling and the sample transport and
storage conditions. Deep or invasive sampling is the
most appropriate [24] and should enable de-escalation,
which is facilitated if documentation is available
[25, 26].
For patients with ventilator-associated pneumonia
(VAP), three studies compared the invasive strategy with
Table 4 Recommendations for field 5: microbiological data: how
to use them to reduce antibiotic consumption
Recommendation
For rapid de-escalation and rational antibiotic use, we
recommend collecting bacteriological samples, if possible
before any antibiotic therapy
1C
In the patients with ventilator-associated pneumonia (VAP),
before the antibiotic treatment onset, we recommend
collecting respiratory samples for quantitative culture, in
order to reduce exposure to antibiotics
1C
We recommend that the results of respiratory specimen Gram
stain are communicated to the clinician without delay
1C
In the absence of signs of severe VAP, if direct examination is
negative, we suggest not initiating empirical antibiotic
treatment
2C
In the presence of signs of severe VAP, we suggest starting
antibiotic treatment based on result of direct examination
(or empirically if direct examination is negative)
2C
A first culture result should be available in the 24 h following
sampling
UG
If the blood culture is positive, we recommend doing bacterial
identification and antibiotic susceptibility testing directly
using the blood culture bottle
1B
If the culture is positive, we suggest tailoring antibiotic
treatment early after rapid bacterial identification by mass
spectrometry
2C
In positive blood cultures with clustered Gram-positive cocci
on direct examination, we recommend using rapid tests to
detect the presence of S. aureus and to determine methicillin
(oxacillin) susceptibility
1B
We recommend determining the minimum inhibitory
concentrations, as recommended by the European
Committee on antimicrobial susceptibility testing, and
communicating them to clinicians
1B
After discussion between microbiologist and clinician, we
suggest determining the minimum inhibitory concentration
for specific infected sites and bacterial species
1C
In the patients with community-acquired pneumonia, if
urinary pneumococcal antigen is positive in adults, we
suggest stopping antibiotics, considering intracellular
bacteria. If there is no urinary pneumococcal antigen,
diagnosis of pneumococcal pneumonia should not be
discarded
2B
If there is urinary Legionella antigen, we suggest stopping the
prescribed b-lactam. When there is no urinary Legionella
antigen, the diagnosis of Legionella pneumonia should not
be discarded
2B
Table 3 Recommendations for field 1: link between resistance of
bacteria and the use of antibiotics in intensive care
Recommendation
Data on local and nationwide bacterial epidemiology must be
used
UG
Scientific societies must communicate (through journals and/
or websites) existing data on the epidemiology of bacterial
infections acquired in intensive care units, gathered by
surveillance networks
UG
We recommend using local epidemiological data (intensive
care units, healthcare facilities) that specify the rate of
bacterial species isolated by type of infection and the rate of
resistance by species
1C
The antibiotic consumption calculated as defined daily dose
(DDD) should be monitored for all intensive care units,
globally and for specific antimicrobial drug classes (notably
carbapenems and fluoroquinolones)
2D
quantitative cultures (bronchoalveolar lavage or protected
specimen brush sampling) and the non-invasive strategy
with qualitative or semi-quantitative cultures of tracheal
aspirates. One study showed that invasive sampling re-
duced mortality and increased the number of days without
antibiotic [27]. The second study showed that this practice
reduced the duration of empirical antibiotic therapy,
without increasing time on ventilation or morbidity and
mortality [28]. The largest study did not confirm these
results, but it did not use invasive sampling to guide an-
tibiotic therapy [29]. The sensitivity of direct testing is
closely associated with the quantity of bacteria present:
between 103 and 105 bacteria/mL, 60 % of direct tests
give positive findings. A meta-analysis indicated a nega-
tive predictive value of 91 % and a positive predictive
value of 40 % for an approximately 30 % prevalence of
VAP [30].
Depending on the study, automated systems for liquid
samples provide bacterial identification and antibiotic
susceptibility results in 3–6 and 7–13 h, respectively.
However, this means that the results become available
outside laboratory hours. Real-time transmission of the
results to clinicians demands reorganization of human
resources [31]. Mass spectrometry provides identification
in a few minutes, with 84–94 % agreement with con-
ventional techniques.
Bacterial identification and antibiotic susceptibility
testing using liquid directly from positive blood culture
bottles can reduce by 20 % the consumption of antibiotics
[32]. Bacterial identification is possible directly by mass
spectrometry (average time 30 min) with good agreement
(80–98 %) as compared with conventional methods,
particularly for Gram-negative bacilli [33]. The time
gained (1.2–1.5 days) enables earlier adaptation of an-
tibiotic therapy in 35 % of patients with bacteraemia (vs.
21 % if adaptation is only done on reading of the Gram
staining results), plus a 5.5–11.3 % increase, depending
on the study, in the proportion of patients correctly treated
[33]. Earlier bacterial identification and antibiotic sus-
ceptibility results in the case of bacteraemia reduce
hospital stay and costs [34].
Mass spectrometry can be used for bacterial identifi-
cation in a few minutes, with 84–94 % agreement with
conventional techniques. Bacterial identification enables
adaptation of the antibiotic therapy even if the antibiotic
susceptibility results are not yet known.
The European Committee on Antimicrobial Suscepti-
bility Testing (EUCAST) specifies the antibiotic–bacteria
pairs for which the minimum inhibitory concentration
(MIC) should be reported. The MIC should probably also
be determined for particular infected sites (endocarditis,
bone infections etc.) and for potentially resistant bacterial
species (e.g. Pseudomonas aeruginosa, Steno-
trophomonas maltophilia, Acinetobacter, Staphylococci
and glycopeptide antibiotics).
It is difficult to establish the impact of the use of
urinary antigen tests [35–37]. In an interventional study,
urinary antigen tests for Streptococcus pneumoniae and
Legionella pneumophila reduced the prescription of
broad-spectrum antibiotics, but at the price of a greater
risk of clinical relapse [36].
Q3: How should antibiotic therapy be chosen to limit
consumption of antibiotics?
a) What impact does colonizaon status have
on the choice of inial anbioctreatment?
Recommendations are presented in Table 5. The required
constrained format has only a limited number of refer-
ences. However, a more detailed argumentation with
more numerous references can be found as ESM.
Rationale
To date, there is no randomized controlled study on re-
ducing quantity or quality of antibiotic therapy using
colonization data. Few teams perform surveillance cul-
tures [38, 39], but caution is needed because the
prescription of empirical antibiotic therapy guided by
tests on endotracheal aspirates (colonization) is not nec-
essarily better than the application of guidelines [40].
Also, such practices could lead to the prescription of
excessive antibiotic therapy based on a result reflecting
colonization status.
Table 5 Recommendations for field 3a: how to use colonization
status?
Recommendation
Routine antibiotic treatment must not be prescribed if a
bacterium, whatever its type, is identified when determining
colonization status, particularly in the case of endotracheal
aspiration
UG
In the presence of signs of severe infection, we suggest
considering colonization status when there are multidrug-
resistant bacteria, whatever the sampling sites, in the choice
of empirical antibiotic treatment for ventilator-associated
pneumonia or nosocomial bacteraemia
2C
When involvement of multidrug-resistant bacteria in
VAP is suspected, studies confirmed the value of taking into
account the colonization status of different sites. Tracheal
aspirates are more reliable than samples collected at other
sites. One study suggests that colonization status was useful
for predicting appropriate antibiotic therapy for bacteraemia
caused by antibiotic-resistant Gram-negative bacteria.
b) When and how should use of carbapenems be
reduced?
Recommendations are presented in Table 6.
Rationale
The use of carbapenems in intensive care is associated
with the emergence of bacterial resistance [41, 42]. To
preserve their efficacy, these molecules should be spared
as much as possible [43].
Given the new EUCAST recommendations on MIC
breakpoints (third-generation cephalosporin and aztreon-
am), based on pharmacokinetic-pharmacodynamic data,
there are possible alternatives to carbapenems [44], in-
cluding b-lactam/b-lactamase inhibitor combinations
[45]. In all cases, these adaptations are made taking into
account the site and the microbiological data (MIC).
c) When and how should use of quinolones be reduced?
Recommendations are presented in Table 7.
Rationale
Fluoroquinolones are widely used because of their unde-
niable clinical value, good oral bioavailability and
favourable diffusion in tissues.
But their use is accompanied by numerous deleterious
effects. The ecological consequences [46, 47] include the
emergence of resistance to fluoroquinolones [21] by mu-
tation of DNA gyrase or of topoisomerase, overexpression
of efflux pumps or lack of permeability. Some of these
mechanisms affect both Gram-negative bacilli and Gram-
positive cocci. They also affect the resistance of other
classes of antibiotics. The emergence of MRSA associ-
ated with fluoroquinolones use should therefore be noted
[48]. There is also an impact on intestinal flora, with the
emergence of highly virulent Clostridium difficile [49] or
the emergence and spread of extended-spectrum b-lacta-
mase-producing Enterobacteriaceae [50, 51].
Moreover, the toxicity and side effects of these antibiotics
may be significant (tendinopathy, phototoxicity, hepatitis, QT
prolongation), which led the European Medicines Agency
(EMA) to issue warnings and restrictions for use.
Table 6 Recommendations for field 3b: how to use carbapenems
Recommendation
We recommend not using carbapenem as empirical
antimicrobial treatment when community-acquired bacterial
infection is suspected
1B
Carbapenem should, however, be considered in patients with a
combination of:
A known history of colonization/infection by extended-
spectrum b-lactamase-producing Enterobacteriaceae or by
ceftazidime-resistant P. aeruginosa, determined within the last
3 months, whatever the sampling site, and
Severe sepsis or septic shock
2D
In terms of empirical antimicrobial treatment, if a hospital-
acquired severe bacterial infection is suspected, we
recommend not prescribing carbapenem solely on the basis
of the nosocomial nature of the infection, but rather
considering the presence of at least two of the following
criteria:
Previous treatment with a third-generation cephalosporin,
fluoroquinolones (including a single dose) or a piperacillin–
tazobactam combination in the last 3 months,
Carriage of extended-spectrum b-lactamase-producing
Enterobacteriaceae or of ceftazidime-resistant P. aeruginosa,
determined within the last 3 months, whatever the sampling
site,
Hospitalization during the last 12 months,
Patient living in a nursing facility or in a long-term care
facility for elderly and carrying an indwelling catheter and/or
a gastrostomy tube,
Ongoing epidemic episode of multidrug-resistant bacteria in
the healthcare institution for which the only treatment option
is carbapenem
1C
After documenting the bacterial infection, an alternative to
carbapenems should be found, according to the infected site
and after microbiologist and clinician interactions
UG
Table 7 Recommendations for field 3c: how to use
fluoroquinolones
Recommendation
In septic shock, in combination with b-lactam antibiotic, we
recommend preferring aminoglycosides to fluoroquinolones
UG
We recommend not prescribing fluoroquinolones when other
antibiotics could be used
UG
Fluoroquinolones can, however, be used in the following
indications:
Proven severe Legionnaires’ disease,
Infections of bone and of the diabetic foot after antibiotic
susceptibility testing,
Prostatitis after antibiotic susceptibility testing
2C
We recommend not prescribing fluoroquinolones repeatedly in
the same patient (take into account prescriptions of
fluoroquinolones within the last 6 months, whatever the
indication)
1B
We recommend not prescribing fluoroquinolones as empirical
monotherapy in severe nosocomial infections
1B
We recommend not prescribing fluoroquinolones for strains of
Enterobacteriaceae that have acquired resistance to
nalidixic acid and/or pipemidic acid
1B
Recommendations are presented in Table 8. As in previous
sections, the reader can refer to the ESM for a wider list of
included studies.
Rationale
Although some studies in the USA reported that up to
12 % of MRSA infections are community-acquired, this
resistance is much less frequent in Europe.
It is important to consider possible MRSA for treating
severe infections in patients with MRSA discharged from
hospital within the last year. Carriage of multidrug-resistant
bacteria is increased in hospital-acquired infections. An-
tibiotic therapy within the last 6 months approximately
doubles the risk of multidrug-resistant bacteria [52]. This
risk is 12 % for MRSA in chronic haemodialysis patients
[53] and 8.6–22 % in long-stay hospital patients [54, 55].
Half of patients are still MRSA carriers at 1 year. The es-
timated median time to MRSA clearance after hospital
discharge is 8.5 months, and may be longer if the patients
are still receiving care and antibiotic therapy [56].
The proportion of MRSA among S. aureus is in con-
stant decline and reached 25.5 % in 2012 in the French
REA-RAISIN database, but the epidemiology varies
greatly from one centre to another.
For CoNS, most international recommendations spe-
cify that only episodes with more than one positive blood
culture should be taken into account. In a retrospective
review, CoNS was found to be responsible for only four
of 369 episodes of VAP in 1955 patients ventilated for
more than 48 h [57]. Review of the diagnosis of VAP
associated with CoNS and the search for an alternative
diagnosis should therefore be routine.
Fowler et al. [58] in a subgroup analysis showed that a
daptomycin dosage of 6 mg/kg/day was not inferior to
standard therapy in the treatment of bacteraemia and right-
sided endocarditis. In a single-centre nonrandomized study
comparing daptomycin with vancomycin (median residual
concentration 17.6 mg/L) in the treatment of MRSA bac-
teraemia with a vancomycin MIC [1 mg/L, there were
fewer failures (20 vs. 48 %) and fewer deaths at 30 days
(3.5 vs. 12.9 %) with daptomycin [59]. Despite the inherent
limitations due to the nature of this study, these findings
suggest that daptomycin should be used in this indication.
High-dose daptomycin can be used to limit the emergence
of resistant mutants even if the modalities of administration
are not yet formally established.
A randomized study of 448 cases of nosocomial
pneumonia [60] showed that the activity of linezolid was
equivalent to that of vancomycin administered discon-
tinuously. The clinical response in per protocol analysis
was even better with linezolid (57.6 vs. 46.6 %;
p = 0.042). However, the vancomycin plasma concen-
trations obtained were below those recommended. In
addition, caution is required in drawing conclusions be-
cause of imbalances between the two groups.
The probability of survival in MRSA bacteraemia is
greater if the vancomycin concentration over time divided
by the vancomycin MIC for the bacterium is high
(AUC24h/MIC ratio[ 400). This target is very difficult to
attain for vancomycin MICs above 1 mg/L [61]. How-
ever, the causal relation between high AUC/MIC and
survival is not demonstrated.
Table 8 Recommendations for field 3d: how to use antibiotics for
MRSA or MRCoNS
Recommendation
Empirical treatment
We recommend not using antibiotics for MRSA (or
MRCoNS) in the empirical antimicrobial treatment of
community-acquired infections
1B
We recommend considering the possibility of MRSA in
severe healthcare-associated infections for patients on
chronic haemodialysis, with chronic wounds, with an
indwelling catheter, or those who reside in long-term care
facilities
1A
We recommend using local epidemiology of the institution
to choose to use (or to avoid) antibiotic treatment for MRSA
(or MRCoNS) for the empirical antimicrobial treatment of
nosocomial infections in the intensive care unit
1C
Documented treatment
We recommend not initiating treatment only because of
positive blood culture with CoNS (whether or not
methicillin-resistant)
1B
In adults and children (except for the neonatal period), we
recommend changing central and arterial lines if several
blood cultures are positive for MRCoNS
1B
In adults and children (except for the neonatal period), if
several blood cultures are positive for MRCoNS, we
recommend initiating treatment, considering the following
disease severity, immunosuppression and antibacterial
resistance pattern
1B
Except for patients with immunosuppression, we
recommend not considering MRCoNS in ventilator-
associated pneumonia and not using antibiotic treatment for
MRCoNS
1A
We suggest using high-dose daptomycin to treat endocarditis
or bacteraemia due to MRSA with vancomycin minimal
inhibitory concentration (MIC)[1 mg/L
2B
We recommend using linezolid in patients with ventilator-
associated pneumonia due to MRSA
1A
In patients with MRSA infection, we recommend to
determine vancomycin MIC
1B
If there is no clinical improvement after 3 days, for an
MRSA infection with MIC[1 mg/L, an alternative to
vancomycin must be used
1C
Depending on the infected site, an anti-MRSA combination
should probably be discussed
UG
MRSA methicillin-resistant Staphylococcus aureus, MRCoNS me-
thicillin-resistant coagulase-negative staphylococci
d) When and how should use of anbiocs for methicillin
(oxacillin)-resistant Staphylococcus aureus and 
coagulase-negave staphylococci be reduced?
Q4: How can antibiotic administration be optimized?
a) When is there a formal indicaon for anbioc treatment?
Recommendations are presented in Table 9.
Rationale
The authors of the Surviving Sepsis Campaign conclude
that effective antibiotic therapy must be administered
within 1 h of recognition of septic shock [62].
Several studies suggest that no more than 4 h should
elapse between the admission and the first dose of an-
tibiotic. However, a meta-analysis comparing early versus
delayed antibiotics did not confirm this result [63]. The
only prospective study included in this analysis even
showed that early antibiotic administration did not shorten
time to clinical stability [64]. In another literature analysis
of the level of proof supporting a short time to first an-
tibiotic dose in community-acquired pneumonia, the
authors emphasized that reduction in the time between
admission and the first dose was associated with antibiotic
misuse, without mortality data sufficiently solid to coun-
terbalance this risk.
On the basis of various studies, the 2009 French
guidelines stipulated 3 h (ideally 1 h) as the time between
admission and administration of the first antibiotic dose
[65].
Although the medical literature does not provide
evidence, it seems that ‘good practice’ is to recommend
optimization of the time to first antibiotic dose in the
frail patients, such as those with post-splenectomy
fever, neutropenic fever, and bacterial necrotizing der-
matitis.
Recommendations are presented in Table 10. As in
previous sections, additional text and references are
available online as ESM.
Rationale
Critically ill patients (severe sepsis/septic shock, fluid
challenges and vasopressors, haemorrhagic shock, burns,
fever and neutropenia, acute kidney failure, continuous
renal replacement therapy, morbid obesity, children) have
major pathophysiological changes [66, 67]. These chan-
ges result in unpredictable between- and within-individual
pharmacokinetic variability, in particular for hydrophilic
antibiotics (aminoglycosides, vancomycin, b-lactam an-
tibiotics) [68, 69]. Plasma and infected site antibiotic
concentrations may be subtherapeutic, leading to clinical
failure and development of bacterial resistance. Con-
versely, kidney and/or liver failure may result in toxic
concentrations [70]. In children, this variability is in-
creased by large age-related differences in volume of
distribution, metabolism and elimination.
Pharmacokinetic/pharmacodynamic approaches show
the value, in terms of clinical efficacy, toxicity and pre-
vention of resistant mutants, of measuring the peak
plasma concentration of aminoglycosides, which are hy-
drophilic antibiotics with concentration-dependent
activity and a narrow therapeutic index [69].
b) When should therapeuc drug monitoring (TDM) 
of anmicrobials be performed? 
Table 9 Recommendations for field 4a: when is there a formal
indication for antibiotics?
Recommendation
We recommend starting empirical antibiotic therapy within
1 h after recognition of septic shock
1B
In patients with suspected severe community-acquired
pneumonia, before any antibiotic therapy, we suggest
considering other diagnoses within the first 4 h after
admission, thus avoiding unnecessary prescription
2B
In bacterial meningitis, we recommend to administer
antibiotics within the 3 h after hospital admission, and
ideally within 1 h
1B
The time to first antibiotic dose should probably be minimized
in frail patients (asplenic or neutropenic patients) or in life-
threatening infections (bacterial necrotizing cellulitis,
purpura fulminans, septic shock etc.)
UG
Table 10 Recommendations for field 4b: when is antibacterial
dosing needed?
Recommendation
Given large unpredictable pharmacokinetic variability, we
recommend therapeutic drug monitoring (TDM) of
antibiotics in intensive care unit adults and paediatric
patients
1B
In all intensive care unit patients, we suggest measuring the
peak plasma concentration of aminoglycosides 30 min after
the first dose (administered in 30-min infusion). If the
concentration is below the target the next dose should be
increased
2C
We suggest measuring the residual concentration of
aminoglycosides in order to avoid toxicity associated with
cumulative administrations, especially in patients with renal
failure
2C
In adults and children, we recommend determining the steady-
state vancomycin concentration in the case of continuous
infusion after a loading dose, or the residual concentration in
the case of discontinuous administrations
1B
For assessing efficacy and toxicity, we suggest determining
residual concentrations of broad-spectrum b-lactam
antibiotics, in discontinuous and prolonged administration,
or of the steady-state concentration in continuous infusion
2C
The bactericidal activity of vancomycin is AUC24h/
MIC-dependent. AUC24h cannot be monitored routinely,
but it correlates with residual concentration, which should
therefore be measured. In discontinuous administration, the
residual concentration must be determined before admin-
istration of the fourth dose. The target for residual
concentration or steady-state concentration in continuous
infusion is around 20 mg/L. It can be higher for the treat-
ment of specific infected sites (central nervous system,
cardiac vegetations or bone).
c) Should certain methods be used to opmize anbioc
administraon (route of administraon [intravenous, 
local], dosage)?
Recommendations are presented in Table 11.
Rationale
For b-lactam antibiotics, the percentage time above the
MIC, which varies according to the antibiotic (50–60 %
for penicillins, 60–70 % for cephalosporins) [71] and the
bacterium, is the best pharmacodynamic predictor of
therapeutic efficacy. There is a clear and compelling ra-
tionale suggesting that the bactericidal activity of b-
lactam antibiotics increases when the plasma concentra-
tions increase to 4–6 times the MIC. However, few
published data correlated achievement of these targets
and the microbiological or clinical outcome of the pa-
tients [72]. In intensive care unit patients, Mohr et al. [73]
suggested that a percentage time above the MIC of 100 %
was associated with a Cmin/MIC ratio above 5 as a
pharmacodynamic target for b-lactam antibiotics. Li et al.
[74] confirmed this target, showing that this ratio is pre-
dictive of clinical success in the treatment of lower
respiratory tract infection.
Pharmacokinetic studies and modelling data agree: the
administration of b-lactam antibiotics by continuous or
prolonged (3 or 4 h) intravenous infusion increases the
time spent above the MIC between two administered
doses. Several studies suggested that prolonged infusion
(3 or 4 h) of b-lactam antibiotics (cefepime, piperacillin–
tazobactam, carbapenems) was associated with mortality
reduction. Lastly, in a meta-analysis, Falagas et al. [75]
showed 10.8 % mortality in patients treated by prolonged
infusion of carbapenems or piperacillin–tazobactam,
compared with 16.8 % in patients treated by intermittent
perfusion (p = 0.03).
Several studies on ICU patients showed that con-
tinuous infusion of piperacillin–tazobactam, meropenem,
ticarcillin–clavulanate, or ceftazidime produced plasma
concentrations above the MIC more frequently than
intermittent infusion. On the other hand, evaluations, in-
cluding meta-analyses, of the clinical benefit of
continuous intravenous infusion of b-lactam antibiotics
did not show the previously mentioned theoretical phar-
macokinetic advantage of this mode of administration.
Failure to demonstrate the greater efficacy of continuous
infusion may stem from methodological considerations,
instability of the antibiotics, particularly penems, an
inoculum effect or concentrations that are too low at the
site of the infection.
Recent in vitro and clinical studies show that an
AUC24h/MIC ratio greater than 400 is predictive of the
clinical efficacy of vancomycin treatment of pneumonia
and MRSA bacteraemia. Clinical studies directly com-
paring continuous and intermittent intravenous infusion
of vancomycin are contradictory [76]. However, con-
tinuous infusion does achieve target plasma
concentrations more rapidly and limits the number of
blood assays as well as the cost of treatment. In a Monte
Carlo simulation study, in patients with severe sepsis, a
loading dose of 35 mg/kg seems necessary to quickly
reach a concentration of approximately 20 mg/L, fol-
lowed by continuous infusion of 35 mg/kg to maintain
this target concentration [77].
In vitro and animal studies showed that the develop-
ment of bacterial resistance is affected by antibiotic
concentrations. Some pharmacodynamic variables (AUC/
MIC, peak/MIC, AUC/mutant prevention concentration,
Table 11 Recommendations for field 4c: how to administer
antibiotics
Recommendation
For intensive care patients with severe infections, we suggest
maintaining the plasma concentrations of b-lactam
antibiotics above MIC for at least 70 % of the time in order
to increase success rate
2C
We suggest achieving a higher target (Cmin/MIC[4–6) 2C
In intensive care unit patients, we recommend administering
b-lactam antibiotics (cefepime, piperacillin–tazobactam,
meropenem and doripenem) by intravenous infusion for 3 or
4 h to treat severe infections, especially if the identified
bacteria have high MICs
1B
We suggest administering by continuous infusion antibiotics
such as carbapenems (meropenem and doripenem),
ceftazidime and piperacillin–tazobactam for the treatment
of severe infections when there is a risk of
pharmacodynamic failure (deep infection sites, major
pharmacokinetic changes, high MIC)
2C
We recommend administering vancomycin by continuous
infusion, after administration of a loading dose, to reach
early target plasma concentrations, which are determinant
for its efficacy
1B
We suggest using prolonged or continuous infusion of
antibiotics to prevent the emergence of bacterial resistance,
particularly with regard to certain strains (S. aureus, P.
aeruginosa, Enterobacteriaceae)
UG
time above the mutant prevention concentration) have
been correlated with the emergence of resistant strains of
Enterobacteriaceae. However, the theoretical advantages
of continuous administration of antibiotics have not been
confirmed by clinical studies of high level of evidence
[78].
d) Anbioc combinaons: indicaons and duraon
Recommendations
Very few studies offer direct, consistent arguments which
allow one to assess the balance between the benefits and
risks of using antibiotic combinations. Thus, the group
issued ungraded statements. These are presented in
Table 12.
Rationale
Monotherapy might be sufficient for VAP on two
conditions: time to onset from intubation of less than
7 days and the patient has received no previous recent
antibiotic therapy. Length of hospital stay before intu-
bation should also be considered. This ‘monotherapy’
approach should probably be extended to all hospital-
acquired pneumonia without risk factors for multidrug-
resistant bacteria.
Despite a low level of evidence, empirical treatment
with a combination of antibiotics is usually recom-
mended in the most critically ill (septic shock) or frail
(blood cancer) patients, especially as they are at risk of
infection by multidrug-resistant bacteria [62, 79].
However, even in frail patients, there should be a
collective understanding of the fundamental importance
of rational use of these combinations of antibiotics in
order to avoid the emergence of multidrug-resistant
bacteria [80].
Q5: Review and duration of antibiotic treatments
Recommendations are presented in Table 13.
Rationale
Few studies evaluated strategies for shortening the length
of antibiotic treatments in intensive care units. Several
strategies have been used: empirical reduction of treat-
ment duration [81], short course of empirical antibiotic
therapy [82] and daily assay of procalcitonin [83].
Studies showed that the duration of antibiotic therapy
is reduced by following recommendations to interrupt
antibiotic therapy when procalcitonin plasma concentra-
tions decrease by 80–90 % from the initial value or below
a threshold, most often 0.5 ng/mL [84]. Some of these
studies included patients with all types of infections in
intensive care units, but most focused on lower respira-
tory tract infections. Lastly, it should be noted that
immunocompromised patients (neutropenia, blood
Table 12 Recommendations for field 4c: antibiotic combinations
Recommendation
If there are no risk factors for multidrug-resistant bacteria, we
suggest using empirical monotherapy to treat hospital-
acquired pneumonia
UG
We suggest using empirical combination treatment for patients
with shock, neutropenia or suspected infection by
multidrug-resistant bacteria
UG
Table 13 Recommendations for field 5: reassessment of antibiotic
treatments
Recommendation
We recommend reassessing antibiotic treatment in all intensive
care unit patients at 48–72 h and de-escalated in light of the
clinical conditions and microbiological data
1C
With respect to calcitonin:
We suggest using procalcitonin to guide the interruption of
antibiotic therapy in intensive care unit patients, especially
those with lower respiratory tract infections. When plasma
procalcitonin concentration is below 0.5 ng/mL or has
decreased by over 80 % from the peak value, antibiotic
treatment can be stopped
2B
Regarding reassessment, we recommend implementing local
recommendations in order to reduce antibiotic exposure
1B
We suggest assaying procalcitonin every 48–72 h after day 3,
to reduce the length of antibiotic therapy
2B
When the initial antibiotic treatment is adequate for non-
immunosuppressed patients with ventilator-associated
pneumonia, we suggest limiting the total duration of
treatment to 8 days, irrespective of the causative organisms
2B
Outside particular clinical situations, we recommend limiting
treatment of a community-acquired infection to 5–7 days
1B
Apart from S. aureus bacteraemia, we recommend limiting
treatment of catheter-associated bacteraemia to 5–7 days if
the blood cultures become negative in the first 3 days of
treatment, if the catheter has been removed and in the
absence of secondary infected sites
1B
We recommend organizing, in each intensive care unit, a
regular (e.g. at least weekly) multidisciplinary staff meeting
in order to improve the quality of antibiotic treatment and
the rate of de-escalation and to limit the antibiotic use
1B
We recommend implementing antibiotic treatment protocols in
order to improve the patient outcomes and to limit the
emergence of resistance
1C
disease, organ transplantation, receiving immunosup-
pressive treatment) were excluded from these studies.
Four randomized controlled studies compared two
fixed treatment durations in non-immunocompromised
adult patients with VAP. A fifth study, in neonatology,
concerned bacteraemia. Other studies compared strategies
using antibiotic therapy duration guided by clinical pro-
gression, biomarker kinetics or the use of antibiotic
therapy protocols.
In VAP identified by microbiological criteria, 8-day
compared with 15-day antibiotic therapy did not reduce
28-day survival, including when the causative organism
was a non-fermenting Gram-negative bacillus (23 vs.
30 %, respectively). Relapse rate did not differ between
the two strategies, except in the case of non-fermenting
Gram-negative bacilli: 21/64 (32.8 %) in the 8-day group
versus 12/63 (19 %) in the 15-day group [81].
In non-immunocompromised patients without criteria
of severe disease who have an uncomplicated community-
acquired respiratory, intra-abdominal, or urinary infection
of satisfactory clinical progression in the first 5 days, 5- to
7-day antibiotic therapy does not involve a greater risk of
treatment failure than longer antibiotic therapy, including
in patients with bacteraemia [85]. Apart from a S. aureus
bacteraemia, or from a complicated bacteraemia, treat-
ment should probably be limited to 5–7 days for a
catheter-related bacteraemia if blood cultures become
negative in the first 3 days of treatment and if the catheter
has been removed [86, 87].
The advantages of a specialized consultation (infec-
tious diseases physicians) with the intensive care unit
team are still open to debate. Five nonrandomized, single-
centre, before-and-after studies examining this question
have evaluated the consumption of antibiotics, the ap-
propriateness of the antibiotics prescribed compared with
the recommendations, the increasing cost of antibiotics
and in some cases mortality [88].
There are no intensive care units studies that
specifically assess the impact of antibiotic therapy pro-
tocols on resistance. There are only six studies (five of
which are prospective before-and-after studies; no ran-
domized studies) of low level of evidence. They suggest
that the use of protocols improves the outcomes of pa-
tients and limits the emergence of resistance to
antibiotics.
Discussion
These guidelines are aimed at reducing the spread of
multidrug-resistant pathogens related to the overuse of
antibiotics in intensive care units. The multidisciplinary
expert panel selected 67 relevant recommendations that
should support the decision to improve antibiotic
stewardship at the bedside. These guidelines should fa-
cilitate the intensivist decisions for avoiding unnecessary
antibiotic initiation, using narrow-spectrum antibiotics if
possible, and interrupting early antibiotics. In contrast,
patients requiring antibiotics should receive an adequate,
early and efficient treatment. This strategy should mini-
mize the development of resistance and offset the lack of
new molecules. As experts, our role now is to convey
these guidelines in each institution.
The first strength of these guidelines is the multidisci-
plinary nature of the expert panel group. Thus, adult
intensivists, infectious disease specialists, epidemiologists
and microbiologists discussed together throughout the
elaboration process. Paediatric intensivists have also par-
ticipated to produce recommendations for the specific
paediatric population. The second strength is the adhesion to
a meticulous process of methodology. The literature analysis,
the elaboration of summaries of evidence and then the de-
termination of the strength of the recommendations followed
the GRADE methodology (see ‘‘Methodology’’ section).
However, one can discuss several limitations. De-
tractors can note a lack of details, making it difficult to
transfer these guidelines in their routine practice. For in-
stance, we did not detail the rules for adapting the
antibiotic dosages in patients with renal failure. The
readers are invited to refer back to recent papers [67–69].
De-escalation in real-life practice remains unclear, prob-
ably reflecting the lack of strong agreement between
experts [9, 25, 26, 89–93]. Several aspects of our practice
were not reported in the guidelines. The role of historical
molecules (fosfomycin, minocycline etc.) could have
been expanded [4]. The experts, probably as a result of
their routine practice, did not consider entirely these old
antibiotics. Aerosolizing of antibiotics was not developed,
whereas there is a substantial amount of data on such a
strategy [94–96]. However, in routine, aerosol antibiotics
remain a relatively rare practice. We probably did not
stress enough the need to avoid most prophylactic an-
tibiotics. That was a weakness of the guidelines. One
should nevertheless note that strategies based on the use
of selective digestive decontamination resulted in a large
decrease of antibiotic use [97]. The goal of our group was
not to be exhaustive but to produce a few recommenda-
tions that were eligible in routine practice. Finally, a few
recommendations may seem provocative for the readers.
For example, the duration of treatment for pseudomonal
infections might be questionable [98]. Our goal was
consistently to encourage the reduction of antibiotic use,
and we analysed the literature in this single way. In the
ESM, the readers will find the argumentation based on our
data assessment.
We reported above the guidelines as stated by the
expert panel group. According to our methodology, we
cannot change the content and meaning of each recom-
mendation. We acknowledge that some recommendations
are a matter of debate.
To date, the challenge is to diffuse, improve knowl-
edge and implement these guidelines. In each institution,
their appropriation should stimulate multidisciplinary
discussions resulting in better knowledge of local epi-
demiology, rate of antibiotic use and finally protocols for
improving the stewardship of antibiotics.
We hope these efforts will contribute to limit the
emergence of resistant bacteria, and we are committed to
assess their impact on this issue.
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Appendix
Recommendations by an expert panel from the French
Intensive Care Society (Société de Réanimation de Lan-
gue Française, SRLF) and the French Society of
Anaesthesia and Intensive Care (Société Française
d’Anesthésie et de Réanimation, SFAR), with the par-
ticipation of the French Group for Paediatric Intensive
Care and Emergencies (Groupe Francophone de
Réanimation et Urgences Pédiatriques, GFRUP), the
French Microbiology Society (Société Française de Mi-
crobiologie, SFM), the French Infectious Diseases Society
(Société de Pathologie Infectieuse de Langue Française,
SPILF), and the French Society for Hospital Hygiene
(Société Française d’Hygiène Hospitalière, SF2H).
Expert panel coordinator: J-P. Bedos (Versaille).
Expert panel: Bernard Allaouchiche (Lyon), Laurence
Armand-Lefèvre (Paris), Olivier Baldesi (Aix), Lila
Bouadma (Paris), Dominique Decré (Paris), Samy
Figueiredo (Le Kremlin-Bicêtre), Rémy Gauzit (Paris),
Benoit Guery (Lille), Nicolas Joram (Nantes), Boris Jung
(Montpellier), Sigismond Lasocki (Angers), Alain Lepape
(Lyon), Fabrice Lesage (Paris), Olivier Pajot (Argenteuil),
François Philippart (Paris), Bertrand Souweine (Cler-
mont-Ferrand), Pierre Tattevin (Rennes), Jean-François
Timsit (Paris), Jean Ralph Zahar (Angers).
Executive committee: C. Bretonnière (Nantes), C.
Milesi (Montpellier), M. Leone (Marseille), B. Misset
(Paris).
SRLF reference and evaluation commission: Cédric
Bretonnière, Karim Chaoui, Aurélie Cravoisy, Michel
Djibré, Laurence Donetti, Laurent Dupic, Fabienne Fieux,
Dominique Hurel, Virginie Lemiale, Olivier Lesieur,
Martine Lesny, Pascal Meyer, Christophe Milési, Benoit
Misset, Mehran Monchi, David Orlikowski, David Os-
man, Jean-Pierre Quenot, Daniel Da Silva, Lilia Soufir,
Thierry Van Der Linden, Isabelle Verheyde.
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